Closing Thoughts, Future Perspectives, and Key Takeaways in the Treatment of Epithelioid Sarcoma
Panelists discuss how early recognition, accurate diagnosis through histopathology and molecular testing, and multidisciplinary collaboration are critical for optimizing treatment strategies in epithelioid sarcoma (ES), while future research into targeted therapies holds promise for improving outcomes, especially in advanced cases.
Summary for Physicians: Key Takeaways and Future Perspectives on ES Diagnosis and Treatment
The diagnosis of ES requires a high level of clinical suspicion due to its rarity and varied presentation. Early recognition is crucial, and histopathologic examination combined with molecular testing (eg, INI1 loss) is essential for accurate diagnosis. Multidisciplinary collaboration is key in determining the most appropriate treatment strategy, which often involves a combination of surgery, radiation, and possibly systemic therapies.
Treatment outcomes are influenced by the disease subtype, with the proximal (large cell) form associated with worse prognosis due to its aggressive nature and propensity for metastasis. As ES is highly prone to recurrence and metastasis, close monitoring posttreatment is essential.
Looking ahead, there is a need for better-targeted therapies and clinical trials to improve outcomes, particularly for those with advanced or metastatic disease. Further understanding of the molecular drivers of ES may lead to more personalized treatment options and improved prognosis for patients.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
